865532-70-3 Usage
Description
Resolvin E2, also known as RvE2, is a specialized pro-resolving mediator (SPM) derived from the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA). It is a potent anti-inflammatory compound that plays a crucial role in the resolution of inflammation and promotes tissue homeostasis. Resolvin E2 possesses unique bioactive properties, making it a promising candidate for various applications in the medical and pharmaceutical fields.
Uses
Used in Pharmaceutical Industry:
Resolvin E2 is used as an anti-inflammatory agent for its ability to block neutrophil infiltration and reduce pro-inflammatory cytokines in the acute peritonitis model. Its potent anti-inflammatory properties make it a potential candidate for the treatment of various inflammatory disorders.
Used in Medical Research:
Resolvin E2 is utilized in medical research as a biomarker for the resolution of inflammation. Its presence in biological samples can indicate the effectiveness of anti-inflammatory treatments and provide insights into the underlying mechanisms of inflammation resolution.
Used in Drug Development:
Resolvin E2 is employed in drug development as a potential therapeutic target for the treatment of inflammatory diseases. Its unique bioactive properties and ability to promote tissue homeostasis make it an attractive candidate for the development of novel anti-inflammatory drugs.
Used in Nutritional Supplements:
Resolvin E2 can be used as a nutritional supplement to support the body's natural inflammatory response. By providing a source of omega-3 polyunsaturated fatty acids, it may help to maintain a healthy balance of pro-inflammatory and anti-inflammatory mediators in the body.
Check Digit Verification of cas no
The CAS Registry Mumber 865532-70-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,5,5,3 and 2 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 865532-70:
(8*8)+(7*6)+(6*5)+(5*5)+(4*3)+(3*2)+(2*7)+(1*0)=193
193 % 10 = 3
So 865532-70-3 is a valid CAS Registry Number.
865532-70-3Relevant articles and documents
Total synthesis of the anti-inflammatory lipid mediator Resolvin E2
Rodriguez, Ana R.,Spur, Bernd W.
, p. 1912 - 1915 (2012)
The total synthesis of Resolvin E2, an endogenous lipid mediator of the resolution of inflammation derived from eicosapentaenoic acid, has been achieved. The chiral hydroxy-groups at C5 and C18 were generated in a simple, efficient, and environmentally friendly manner via an asymmetric Noyori transfer hydrogenation in water using sodium formate as a reducing agent. Pd 0/CuI Sonogashira couplings of the three key fragments and Zn(Cu/Ag) reduction completed the synthesis of Resolvin E2.
Total synthesis and bioactivity of resolvin E2
Ogawa, Seiji,Urabe, Daisuke,Yokokura, Yoshiyuki,Arai, Hiroyuki,Arita, Makoto,Inoue, Masayuki
supporting information; experimental part, p. 3602 - 3605 (2011/02/23)
Image Presented Resolvin E2 is a potent anti-inflammatory compound, derived from eicosapentaenoic acid. The efficient total synthesis of resolvin E2 by taking advantage of its intrinsic pseudoenantiomeric substructures is reported. The synthetic resolvin
RESOLVINS: BIOTEMPLATES FOR NOVEL THERAPEUTIC INTERVENTIONS
-
Page 103, (2008/06/13)
The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
